G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Paolo Strati,Guilin Tang,Dzifa Y. Duose,Saradhi Mallampati,Rajyalakshmi Luthra,Keyur P. Patel,Mohammad Hussaini,Abu-Sayeef Mirza,Rami S. Komrokji,Stephen T. Oh,John Mascarenhas,Vesna Najfeld,Vivek Subbiah,Hagop M. Kantarjian,Guillermo Garcia-Manero,Srdan Verstovsek,Naval Daver +16 more
TL;DR: FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL and FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.
Journal ArticleDOI
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
Elias Jabbour,Naval Daver,Richard E. Champlin,Michael S. Mathisen,Betul Oran,Stefan O. Ciurea,Issa F. Khouri,A. Megan Cornelison,Hady Ghanem,Marylou Cardenas Turanzas,Uday R. Popat,Farhad Ravandi,Sergio Giralt,Guillermo Garcia-Manero,Jorge E. Cortes,Hagop M. Kantarjian,Marcos de Lima +16 more
TL;DR: Initial salvage therapy with Allogeneic hematopoietic stem cell transplantation as initial salvage in patients with primary HiDAC refractory AML is feasible and may yield superior outcomes to salvage chemotherapy.
Journal ArticleDOI
Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment
Guillermo Garcia-Manero,Martin S. Tallman,Giovanni Martinelli,Vincent Ribrag,Hui Yang,Arun Balakumaran,S. Chlosta,Yayan Zhang,B. Douglas Smith +8 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands and can restore antitumor immune activity in solid tumors and hematologic malignancies in patients with MDS.
Journal ArticleDOI
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis
Sergej Konoplev,Xuelin Huang,Harry A. Drabkin,Hartmut Koeppen,Dan Jones,Hagop M. Kantarjian,Guillermo Garcia-Manero,Weina Chen,L. Jeffrey Medeiros,Carlos E. Bueso-Ramos +9 more
TL;DR: Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation in acute myeloid leukemia patients.
Journal ArticleDOI
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner,Jordi Esteve,Kimmo Porkka,Steve Knapper,Norbert Vey,Sebastian Scholl,Guillermo Garcia-Manero,Martin Wermke,Jeroen Janssen,Elie Traer,Sun Loo,Rupa Narayan,Natalia Tovar,Mika Kontro,Oliver G. Ottmann,Purushotham Naidu,Sema Kurtulus,Jessica Makofske,Serena Liao,Anisa Mohammed,Catherine Anne Sabatos-Peyton,Mikael L. Rinne,Uma Borate,Andrew H. Wei +23 more
TL;DR: With sabatolimab + HMA, the most common gr ≥3 treatment-emergent adverse events (TEAEs) in pts with ND AML and HR-MDS, respectively, were thrombocytopenia and pneumonia, and results are reported here for the Dec and Aza arms both combined and separately.